Correction to: Darinaparsin: First Approval

An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan and is currently in clinical development for this indication in China, the USA and the EU.

Should read:

An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan, and preparation for the next stage of the clinical development program for this indication is currently underway in China, the USA and the EU.

Introduction, fourth paragraph, first sentence, which currently reads:

Intravenous darinaparsin is currently in clinical development for relapsed or refractory PTCL in China, the USA and the EU [8].

Should read:

Preparation for the next stage of the clinical development program of intravenous darinaparsin in relapsed or refractory PTCL is currently underway in China, the USA and the EU [8].

Author information

Authors and Affiliations

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand
James E. Frampton

Authors

James E. Frampton
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. Correction to: Darinaparsin: First Approval. Drugs 82, 1611 (2022). https://doi.org/10.1007/s40265-022-01807-y

Download citation

Published: 14 November 2022
Issue Date: November 2022
DOI: https://doi.org/10.1007/s40265-022-01807-y

Use our pre-submission checklist

Avoid common mistakes on your manuscript.